NCT01438112View on ClinicalTrials.gov

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Transitional Cell CarcinomaBladder CancerCarcinoma in SituCarcinoma in Situ Concurrent With Papillary Tumors
Interventions
BIOLOGICAL

CG0070 Adenovirus Vector

CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six

OTHER

Control Arm: Quadruple Choice

Quadruple Choice Treatment Options: (same as listed above)

Trial Locations (7)

27157

Wake Forest University Health Sciences, Winston-Salem

37232

Vanderbilt University Medical Center Department of Urologic Surgery, Nashville

60637

University of Chicago, Department of Surgery, Section of Urology, Chicago

90024

UCLA Institute of Urological Oncology, Los Angeles

92093

University of California, San Diego- Moores Cancer Center, La Jolla

95817

University of California, Davis- Cancer Center, Sacramento

85032-2129

BCG Oncology, Phoenix

Sponsors

Lead Sponsor

CG Oncology, Inc.
All Listed Sponsors
lead

CG Oncology, Inc.

INDUSTRY